The production of chemokines, CCL3 and CCL4, is increased upon BCR activation in MCL [6], chronic lymphocytic leukemia (CLL) [7] and diffuse large B cell lymphoma (DLBCL) [8], and such effects can be impaired by Ibrutinib treatment, which also significantly decreases chemokine receptor CXCR4 expression in MCL [6] and CLL [9]. Here, CCL3 is linked to mantle cell lymphoma.